DENVER, CO--(Marketwire - Jan 9, 2012) - Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: [ OMBP ]), a clinical-stage biopharmaceutical company, today announced that it will present at Noble Financial Capital Markets' Eighth Annual Equity Conference being held January 17 & 18 at the Hard Rock Hotel & Casino in Hollywood, Florida.

Dr. James Crapo, Omni Bio's chief executive officer, is scheduled to speak on Wednesday, January 18 at 1:30 p.m. Eastern time (11:30 a.m. Mountain time).

Conference and presentation details will be made available at the Omni Bio website at [ www.omnibiopharma.com ]. An archived presentation will be available on the website for 30 days.

About Omni Bio Pharmaceutical, Inc.

Omni Bio Pharmaceutical, Inc. ([ www.omnibiopharma.com ]) is a clinical-stage biopharmaceutical company that has licensed potential new indications for an existing FDA approved drug -- Alpha‐1 antitrypsin (AAT). Omni Bio's core technology is based on issued patents and patent applications licensed from the University of Colorado Denver (UCD) and a privately held company, Bio Holding, Inc. Omni Bio's lead development program has been funding research and a human clinical trial to evaluate the effectiveness of AAT in the treatment of Type 1 diabetes. Novel discoveries made at UCD indicate that AAT has the potential to address a variety of indications in the areas of diabetes, transplant rejection and bacterial and viral disorders.

Omni Bio is also a significant investor in BioMimetix Pharmaceutical, Inc. (BioMimetix), a recently formed biopharmaceutical corporation. BioMimetix is the exclusive licensee of an issued patent held by Duke University, and intends to develop a new class of patented compounds for the treatment of various diseases including radiation toxicity during the treatment of cancer using radiation therapy.